SOW
KLRS

State of Wyoming’s Kalaris Therapeutics KLRS Stock Holding History

State of Wyoming’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14
Closed -$2K – 2183
2022
Q1 		$2K Buy
14
+5
+56% +$997 ﹤0.01% 1715
2021
Q4 		$3K Sell
9
-4
-31% -$1.86K ﹤0.01% 1760
2021
Q3 		$8K Sell
13
-13
-50% -$6.02K 0.01% 1056
2021
Q2 		$12K Buy
26
+14
+117% +$7.23K 0.01% 998
2021
Q1 		$7K Buy
+12
New +$10.1K 0.01% 425

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State of Wyoming's KLRS Position: Q2 2022 in Review

State of Wyoming sold out of Kalaris Therapeutics (KLRS) in Q2 2022, closing a stake of 14 shares — an estimated $2K sold.

State of Wyoming first reported a position in KLRS in Q1 2021 and held it in 5 quarters. The position peaked at $12K in Q2 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q2 2022.

  • State of Wyoming reported no remaining Kalaris Therapeutics position as of Q2 2022 after selling out during the quarter.
  • State of Wyoming sold 14 Kalaris Therapeutics shares in Q2 2022, an estimated $2K.
  • State of Wyoming first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 5 quarters.
  • State of Wyoming's Kalaris Therapeutics position peaked at $12K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2022.

Based on State of Wyoming's 13F filing for Q2 2022, filed 15 Aug 2022.